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Patients suﬀering from a wide variety of diseases may beneﬁt
from cell-based therapies. Transplantation of nonimmuno-
genic cells may be able to functionally repair or replace
damaged tissue or missing cells with important roles. How-
ever, currently available cell-based therapies are limited in
scope and have almost exclusively relied on autologous and
allogenic sources of transplantable cells. Further prohibiting
their widespread use, donor-limited cells can be diﬃcult
to obtain, have inadequate expansion capabilities, and may
result in graft-versus-host disease. Due to their inexhaustible
capabilitytoexpandandwide-rangingdiﬀerentiation poten-
tial, human embryonic stem cells (hESCs) and the less
ethicallycontroversialinducedpluripotentstemcells(iPSCs)
hold great promise in serving as alternative cell sources for
regenerative medicine and may oﬀer many advantages over
currently available cell-based therapies. They may help treat
diseases such as atherosclerosis, diabetes, stroke, liver, kidney
disease as well as a variety of hematologic and neurologic
disorders. This special issue focuses on the promise and
therapeutic potential of hESC/iPSCs in a wide variety of
diseases. It highlights important advances as well as common
problems that must be resolved before the therapeutic
potential of hESC/iPSCs becomes clinical reality.
One of the biggest safety considerations hindering clin-
ical application of hESC- and iPSC-based products is the
risk of tumor formation. Pluripotent cells like hESCs and
iPSCS harbor an intrinsic ability to divide and self-renew
without undergoing senescence. Many hESC-/iPSC-based
therapies are based on derivatives of the cells that are no
longer pluripotent, yet the risk of a surviving pluripotent cell
possibly contaminating the therapeutic cell preparation is a
major safety issue. Ineﬃcient diﬀerentiation and incomplete
maturation top the list of hurdles that need to be overcome
in order to bring hESC-based therapies to the clinic. As
many articles in this special issue illustrate, directing the in
vitro diﬀerentiation of hESCs into therapeutically useful cell
t y p e si sac o m p l e xa n do f t e nd i ﬃcult process. From altering
cytokine cocktails and media formulations to using scaﬀolds
and 3-dimensional matrices, researchers have applied many
diﬀerent strategies to increase the eﬃciency of producing the
desired cell types from hESCs and iPSCs. Also hampering
iPSCresearch,reprogrammingeﬃciencies,andqualityofthe
resulting iPSC lines vary greatly and need to be optimized
before iPSCs can routinely be used to generate patient-
speciﬁc therapeutic cells. While these issues are being
resolved in cell culture labs, hESC-/iPSC-based therapies will
also have to undergo rigorous preclinical testing in suitable
animal models of disease. As the reader will discover in
the ensuing articles, some hESC-/iPSC-based therapies are
already being examined in animal models and showing signs
of therapeutic utility.
Beginning with a review article on tissue engineering,
the reader of this special issue will ﬁrst learn about the
use of hESCs to generate chondrocytes, osteocytes, and
mesenchymal stromal cells for bone and vascular disease
therapies.Thenexttwoarticlesreviewcell-basedtherapiesto
treat hematologic disorders and type 1 diabetes, respectively.
The ﬁrst paper describes how hESCs/iPSC derivatives may2 Stem Cells International
be able to substitute for red blood cells, platelets, and various
subpopulations of immune surveying white blood cells. The
second article focuses on how hESC/iPSCs can be used to
generate insulin-producing islet cells and may be able to
functionally replace cells of a failing diabetic pancreas. Next,
the reader will learn about cardiovascular disease, ischemia,
and life-threatening damage to the heart muscle. Two back
to back review articles focus on how hESCs and more
speciﬁcally iPSCs can be used to generate cardiomyocytes
and how these powerful cells can improve the function
of a heart weakened by tissue damage. Highlighting the
far-reaching application of hESC-/iPSC-based therapies, the
next two articles move away from the heart and into the
brain. The ﬁrst article introduces the reader to a broad range
of neurologic disorders including those with degenerative,
developmental, genetic, or metabolic roots. It describes how
patient-speciﬁc iPSCs can be used in disease models and
help develop new therapies. The second paper is a primary
researcharticlethatexaminesthetherapeuticutilityofhESC-
derived motor neuron progenitors in rodent models of
spinal muscular atrophy, amyotrophic lateral sclerosis, and
spinal cord injury. Capping oﬀ the broad therapeutic topics
covered in this special issue, the eighth and ﬁnal paper is
a primary research article that brings us back to hESCs
themselvesandtheirinitialderivation.Ethicalconsiderations
surrounding the destruction of human embryos provided
not only the impetus for the development of iPSCs but also,
as this ﬁnal paper discusses, new derivation methods that
avoid the destruction of viable human embryos. From the
diverse collection of papers in this special issue, the reader
should gain a better understanding of why proponents of
hESC/iPSC research lobby so hard for continued research
and development. In the face of rising health care costs and
widespread clinical need, hESCs and/or iPSCs may one day
provide a cost-eﬀective means for large-scale production of
therapeutic cells and revolutionize the ﬁeld of regenerative
medicine.
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